PE04692010A1 - Imiquimod formulations - Google Patents

Imiquimod formulations

Info

Publication number
PE04692010A1
PE04692010A1 PE2009001323A PE0013232009A PE04692010A1 PE 04692010 A1 PE04692010 A1 PE 04692010A1 PE 2009001323 A PE2009001323 A PE 2009001323A PE 0013232009 A PE0013232009 A PE 0013232009A PE 04692010 A1 PE04692010 A1 PE 04692010A1
Authority
PE
Peru
Prior art keywords
quinolin
imidazo
1h
imiquimod formulations
imiquimod
Prior art date
Application number
PE2009001323A
Other languages
Spanish (es)
Inventor
Michael T Nordsiek
Sharon F Levy
James H Lee
James H Kulp
Kodumudi S Balaji
Tze-Chiang Meng
Jason J Wu
Valyn S Bahm
Robert Babilon
Original Assignee
Medicis Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US13953608P priority Critical
Priority to US14473109P priority
Priority to US20514509P priority
Application filed by Medicis Pharmaceutical Corp filed Critical Medicis Pharmaceutical Corp
Publication of PE04692010A1 publication Critical patent/PE04692010A1/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42316709&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE04692010(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061Polyacrylates

Abstract

REFERIDA A UNA FORMULACION FARMACEUTICA QUE COMPRENDE 1-ISOBUTIL-1H-IMIDAZO[4,5-c]-QUINOLIN-4-AMINA O 1-(2-METILPROPIL)-1H-IMIDAZO[4,5-C]QUINOLIN-4-AMINA (IMIQUIMOD) (FIGURA 1) EN UNA CANTIDAD EN PESO DE ENTRE 1,5% Y 4,25% P/PY UN ACIDO GRASO TAL COMO ACIDO OLEICO, ESTEARICO, PALMITICO, ENTRE OTROS. REFERRED TO A PHARMACEUTICAL FORMULATION COMPRISING 1-isobutyl-1H-imidazo [4,5-c] quinolin-4-amine or 1- (2-methylpropyl) -1H-imidazo [4,5-c] quinolin-4- AMINA (imiquimod) (Figure 1) in an amount by weight between 1.5% and 4.25% w / w A FATTY aCID AS oleic acid, stearic, palmitic, and others. TAMBIEN ESTA REFERIDA A UN METODO DE PREPARACION. ALSO refers to a method of preparation. DICHA FORMULACION ES UTIL EN EL TRATAMIENTO DE LA QUERATOSIS ACTINICA This formulation is useful in the treatment of actinic keratosis
PE2009001323A 2008-12-19 2009-12-18 Imiquimod formulations PE04692010A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US13953608P true 2008-12-19 2008-12-19
US14473109P true 2009-01-14 2009-01-14
US20514509P true 2009-01-15 2009-01-15

Publications (1)

Publication Number Publication Date
PE04692010A1 true PE04692010A1 (en) 2010-07-31

Family

ID=42316709

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2009001323A PE04692010A1 (en) 2008-12-19 2009-12-18 Imiquimod formulations
PE2014000347A PE23672014A1 (en) 2008-12-19 2009-12-18 Imiquimod formulations

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2014000347A PE23672014A1 (en) 2008-12-19 2009-12-18 Imiquimod formulations

Country Status (24)

Country Link
US (12) US20110021555A1 (en)
EP (1) EP2378876B1 (en)
AR (1) AR074802A1 (en)
AU (1) AU2009335943A1 (en)
BR (1) BRPI0923164A2 (en)
CL (1) CL2009002183A1 (en)
CO (1) CO6400171A2 (en)
CR (1) CR20110338A (en)
DK (1) DK2378876T3 (en)
DO (1) DOP2011000195A (en)
EA (1) EA201100984A1 (en)
ES (1) ES2720149T3 (en)
HR (1) HRP20190306T1 (en)
HU (1) HUE041944T2 (en)
IL (2) IL213628A (en)
LT (1) LT2378876T (en)
MX (2) MX2011001555A (en)
PA (1) PA8855101A1 (en)
PE (2) PE04692010A1 (en)
PL (1) PL2378876T3 (en)
RS (1) RS58566B1 (en)
SI (1) SI2378876T1 (en)
TW (1) TWI442923B (en)
WO (1) WO2010080345A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100160368A1 (en) 2008-08-18 2010-06-24 Gregory Jefferson J Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy
US20110030089A1 (en) 2008-08-29 2011-02-03 Los Alamos National Security, Llc Transgenic plants with enhanced growth characteristics
US20110030104A1 (en) 2008-08-29 2011-02-03 Los Alamos National Security, Llc Nucleic acids encoding plant glutamine phenylpyruvate transaminase (GPT) and uses thereof
BRPI0923164A2 (en) * 2008-12-19 2016-01-26 Graceway Pharmaceuticals Llc Imiquimod formulations with lower dosage concentration and short dosage regimens for the treatment of actinic keratosis.
PL2453747T3 (en) * 2009-07-13 2018-02-28 Medicis Pharmaceutical Corporation Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts
EA201291442A1 (en) 2010-06-25 2013-04-30 Медисиз Фармасьютикал Корпорейшн Combined therapy with cryosurgery and imicvimode with low dosage for the treatment of actinic ceratosis
US9072876B2 (en) 2010-08-05 2015-07-07 Medicis Pharmaceutical Corporation Pump systems and methods for storing and dispensing a plurality of precisely measured unit-doses of imiquimod cream
US9492682B2 (en) 2011-09-14 2016-11-15 Medicis Pharmaceutical Corporation Combination therapy with low dosage strength imiquimod and photodynamic therapy to treat actinic keratosis
ES2551614T3 (en) * 2011-11-30 2015-11-20 Merz Pharma Gmbh & Co. Kgaa Use of pegylated alcohols for the treatment of actinic keratosis
CA2871490A1 (en) 2012-04-27 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of cpg oligonucleotides co-formulated with an antibiotic to accelerate wound healing
AU2014312086A1 (en) 2013-08-30 2016-03-10 Immunogen, Inc. Antibodies and assays for detection of folate receptor 1
US9619980B2 (en) 2013-09-06 2017-04-11 Immersion Corporation Systems and methods for generating haptic effects associated with audio signals
US9711014B2 (en) 2013-09-06 2017-07-18 Immersion Corporation Systems and methods for generating haptic effects associated with transitions in audio signals
US9576445B2 (en) 2013-09-06 2017-02-21 Immersion Corp. Systems and methods for generating haptic effects associated with an envelope in audio signals
WO2015054400A2 (en) * 2013-10-08 2015-04-16 Immunogen, Inc. Anti-folr1 immunoconjugate dosing regimens
BR112017004893A2 (en) * 2014-09-10 2017-12-12 Univ Washington compositions and methods for the treatment of precancerous skin lesions
WO2017049149A1 (en) 2015-09-17 2017-03-23 Immunogen, Inc. Therapeutic combinations comprising anti-folr1 immunoconjugates

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE24906E (en) 1955-11-18 1960-12-13 Pressure-sensitive adhesive sheet material
US4722941A (en) 1978-06-07 1988-02-02 Kali-Chemie Pharma Gmbh Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof
US4411893A (en) * 1981-08-14 1983-10-25 Minnesota Mining And Manufacturing Company Topical medicament preparations
IL73534A (en) * 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US4751087B1 (en) 1985-04-19 1993-03-02 Riker Laboratories Inc
US4746515A (en) * 1987-02-26 1988-05-24 Alza Corporation Skin permeation enhancer compositions using glycerol monolaurate
US5238944A (en) * 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
SE9601528D0 (en) * 1996-04-23 1996-04-23 Pharmacia Ab Transdermally Administered dextromethorphan as anti-tissue agent
PT1040112E (en) * 1997-12-11 2005-01-31 Minnesota Mining & Mfg Imidazonethydidines and their use in the induction of the biosythesis of cytokins
US20030007939A1 (en) * 1998-07-31 2003-01-09 Howard Murad Pharmaceutical compositions and methods for managing dermatological conditions
IL144028D0 (en) 1999-01-08 2002-04-21 3M Innovative Properties Co Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
US20020058674A1 (en) * 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
US20030072814A1 (en) * 1999-12-16 2003-04-17 Maibach Howard I. Topical pharmaceutical composition for the treatment of warts
US6894060B2 (en) * 2000-03-30 2005-05-17 3M Innovative Properties Company Method for the treatment of dermal lesions caused by envenomation
US20020055517A1 (en) * 2000-09-15 2002-05-09 3M Innovative Properties Company Methods for delaying recurrence of herpes virus symptoms
CA2449754A1 (en) 2001-06-15 2002-12-27 3M Innovative Properties Company Immune response modifiers for the treatment of periodontal disease
EP1450804B9 (en) * 2001-11-29 2009-04-01 3M Innovative Properties Company Pharmaceutical formulations comprising an immune response modifier
US20040265351A1 (en) * 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US7893083B2 (en) * 2003-01-06 2011-02-22 Eugene Mandrea Method of treating genital herpes
CN100558361C (en) * 2003-03-13 2009-11-11 3M创新有限公司 Methods of improving skin quality
US7699057B2 (en) * 2003-03-13 2010-04-20 3M Innovative Properties Company Methods for treating skin lesions
US20040192585A1 (en) 2003-03-25 2004-09-30 3M Innovative Properties Company Treatment for basal cell carcinoma
US20090232755A1 (en) * 2003-07-28 2009-09-17 Leslie Baumann Combination therapies for treating photodamaged skin
US7521459B2 (en) * 2003-07-28 2009-04-21 Metabeauty Inc. Method for treating damaged skin
MXPA06002408A (en) 2003-09-02 2006-06-20 3M Innovative Properties Co Methods related to the treatment of mucosal associated conditions.
CN1922137A (en) 2003-12-31 2007-02-28 太景生物科技股份有限公司 Protease inhibitors
EP1720567A2 (en) * 2004-02-10 2006-11-15 Innate Pharma Composition and method for the treatment of carcinoma
US20080125485A1 (en) * 2004-02-17 2008-05-29 Action Medicines Use of 2,5-Dihydroxybenzene Derivatives for Treating Actinic Keratosis
US20070166384A1 (en) * 2004-04-09 2007-07-19 Zarraga Isidro Angelo E Methods , composition and preparations for delivery of immune response modifiers
US20070196452A1 (en) 2004-06-07 2007-08-23 Jie Zhang Flux-enabling compositions and methods for dermal delivery of drugs
CN1286529C (en) 2004-06-11 2006-11-29 华中科技大学 Skin targeting medicinal composition and its preparation and use
US20060062755A1 (en) * 2004-09-21 2006-03-23 Woodward John R Method of cancer screening; method of cancer treatment; and method of diabetes treatment
DE102004049223A1 (en) * 2004-10-08 2006-04-20 Johannes-Gutenberg-Universität Mainz Preparation for vaccination, vaccination methods, and use of a vaccine preparation
US20060105028A1 (en) * 2004-11-12 2006-05-18 Jie Zhang Systems and methods for treating warts
US8080560B2 (en) * 2004-12-17 2011-12-20 3M Innovative Properties Company Immune response modifier formulations containing oleic acid and methods
EP1844201B1 (en) 2005-02-04 2016-08-24 3M Innovative Properties Company Aqueous gel formulations containing immune response modifiers
WO2007025999A1 (en) * 2005-08-31 2007-03-08 Serentis Limited Use of an aureolysin inhibitor for the treatment of inflammatory skin conditions characterised by colonisation with staphylococcus aureus
US8703753B2 (en) * 2005-09-15 2014-04-22 Biomas Ltd. Use of tellurium compounds for the treatment of actinic keratosis
US20070081962A1 (en) 2005-10-06 2007-04-12 Amit Munshi Novel delivery of immune response modifiers for removal of chronic tattoos
GB0524962D0 (en) * 2005-12-07 2006-01-18 Pharmakodex Ltd Topical pharmaceutical compositions
US20070264317A1 (en) * 2006-05-15 2007-11-15 Perrigo Israel Pharmaceuticals Ltd. Imiquimod cream formulation
CA2659095C (en) * 2006-07-14 2015-04-28 Stiefel Research Australia Pty Ltd Fatty acid pharmaceutical foam
US20100092401A1 (en) 2006-07-18 2010-04-15 Graceway Pharmaceuticals, Llc Immune response modifier formulations
WO2008016475A2 (en) 2006-07-31 2008-02-07 3M Innovative Properties Company Immune response modifier compositions and methods
TW200819435A (en) * 2006-09-15 2008-05-01 Celgene Corp N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same
HUE035308T2 (en) * 2006-09-26 2018-05-02 Celgene Corp 5-substituted quinazolinone derivatives as anti-cancer agents
EP2115140B8 (en) * 2007-01-31 2017-01-25 Chongxi Yu Positively charged water-soluble prodrugs of 1H-imidazo[4,5-c]quinolin-4-amines and related compounds with very high skin penetration rates
US20090018155A1 (en) * 2007-02-08 2009-01-15 Gregory Jefferson J Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy
WO2008118765A1 (en) 2007-03-23 2008-10-02 Graceway Pharmaceuticals, Llc Methods and packages to enhance safety when using imiquimod to treat children diagnosed with skin disorders
US20080280943A1 (en) * 2007-03-23 2008-11-13 Slade Herbert B Methods and packages to enhance safety when using imiquimod to treat children diagnosed with skin disorders
WO2008140713A1 (en) 2007-05-08 2008-11-20 The Brigham And Women's Hospital, Inc Methods and products for treating proliferative disorders
US8636982B2 (en) * 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
GB0715428D0 (en) 2007-08-08 2007-09-19 Imp Innovations Ltd Compositions and uses thereof
US8343498B2 (en) * 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US20090130029A1 (en) * 2007-11-21 2009-05-21 Foamix Ltd. Glycerol ethers vehicle and pharmaceutical compositions thereof
US9439857B2 (en) * 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
KR20100117077A (en) 2008-01-15 2010-11-02 다우 파마슈티컬 사이언시즈, 인코포레이티드 Imiquimod formulation
EP2176408B9 (en) 2008-01-31 2015-11-11 Curevac GmbH NUCLEIC ACIDS COMPRISING FORMULA (NuGiXmGnNv)a AND DERIVATIVES THEREOF AS AN IMMUNOSTIMULATING AGENTS /ADJUVANTS
US20090246156A1 (en) * 2008-03-31 2009-10-01 Audrey Kunin Anti-acne sunscreen composition
NZ588668A (en) * 2008-04-03 2013-01-25 Cognate 3 Uses of helicin and other glucopyranosyloxy benzaldehydes in the treatment of cancer
WO2009134769A1 (en) 2008-04-28 2009-11-05 Novartis Ag Nanoparticles for use in pharmaceutical compositions
AU2009260485B2 (en) 2008-05-30 2015-01-29 Novelix Pharmaceuticals, Inc. Compositions and methods for treatment of inflammation and hyperkeratotic lesions
MX2010013562A (en) 2008-06-26 2011-02-15 Anterios Inc Dermal delivery.
US20100160368A1 (en) 2008-08-18 2010-06-24 Gregory Jefferson J Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy
WO2010050889A1 (en) 2008-10-31 2010-05-06 Moberg Derma Ab Topical composition comprising a combination of at least two penetration enhancing agents
BRPI0923164A2 (en) * 2008-12-19 2016-01-26 Graceway Pharmaceuticals Llc Imiquimod formulations with lower dosage concentration and short dosage regimens for the treatment of actinic keratosis.
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
PL2453747T3 (en) 2009-07-13 2018-02-28 Medicis Pharmaceutical Corporation Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts
US8476225B2 (en) 2009-12-04 2013-07-02 Gilead Sciences, Inc. Antiviral compounds
US9492682B2 (en) * 2011-09-14 2016-11-15 Medicis Pharmaceutical Corporation Combination therapy with low dosage strength imiquimod and photodynamic therapy to treat actinic keratosis

Also Published As

Publication number Publication date
SI2378876T1 (en) 2019-05-31
IL213628D0 (en) 2011-07-31
MX346455B (en) 2017-03-21
US10238644B2 (en) 2019-03-26
AR074802A1 (en) 2011-02-16
US20110263634A1 (en) 2011-10-27
US20110263636A1 (en) 2011-10-27
US8299109B2 (en) 2012-10-30
US20110257219A1 (en) 2011-10-20
DOP2011000195A (en) 2011-12-15
PL2378876T3 (en) 2019-06-28
EP2378876A4 (en) 2012-12-05
US9370509B2 (en) 2016-06-21
LT2378876T (en) 2019-04-25
HUE041944T2 (en) 2019-06-28
WO2010080345A1 (en) 2010-07-15
US20110257218A1 (en) 2011-10-20
TW201040173A (en) 2010-11-16
ES2720149T3 (en) 2019-07-18
HRP20190306T1 (en) 2019-05-03
US20110257216A1 (en) 2011-10-20
IL255163D0 (en) 2017-12-31
CL2009002183A1 (en) 2011-01-07
US20160303111A1 (en) 2016-10-20
PA8855101A1 (en) 2010-07-27
BRPI0923164A2 (en) 2016-01-26
US20110263633A1 (en) 2011-10-27
US20110263635A1 (en) 2011-10-27
EP2378876B1 (en) 2018-11-14
PE23672014A1 (en) 2015-01-10
RS58566B1 (en) 2019-05-31
MX2011001555A (en) 2011-04-14
CR20110338A (en) 2011-11-10
DK2378876T3 (en) 2019-03-11
AU2009335943A1 (en) 2013-10-24
US20130210855A1 (en) 2013-08-15
IL255163A (en) 2019-01-31
US8236816B2 (en) 2012-08-07
CO6400171A2 (en) 2012-03-15
US20110257217A1 (en) 2011-10-20
EP2378876A1 (en) 2011-10-26
IL213628A (en) 2017-11-30
US20110263637A1 (en) 2011-10-27
US20110021555A1 (en) 2011-01-27
EA201100984A1 (en) 2012-01-30
US8222270B2 (en) 2012-07-17
TWI442923B (en) 2014-07-01

Similar Documents

Publication Publication Date Title
CA2818187C (en) Bromodomain inhibitors and uses thereof
JO3187B1 (en) 4-(8-methoxy-1-((1-methoxypropan-2-yl)-2-(tetrahydro-2h-pyran-4-yl)-1 h-imidazo[4,5-c]quinolin-7-yl)-3,5-dimethylisoxazole and its use as bromodomain inhibitor
MY157040A (en) Lipid-containing compositions and methods of use thereof
AR048175A1 (en) Compound pyrazolo (3,4-b) pyridine and its use as PDE4 inhibitor
MX2012007403A (en) Isoindolinone inhibitors of phosphatidylinositol 3-kinase.
TW200626572A (en) Heterocyclic derivatives and their use as therapeutic agents
NZ597193A (en) Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
NZ601754A (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
RS54266B1 (en) Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases
BR112015014592A2 (en) compound, pharmaceutical composition, and method for treating a human
TW200626148A (en) Heterocyclic derivatives and their use as therapeutic agents
PA8759601A1 (en) Derivatives of 2,3-dihydro-imidazo [1,2-c] quinazoline substituted useful for treating diseases and disorders associated with hyper-proliferative Angiogenesis
WO2010122178A3 (en) Cyclohexyl carbamate compounds as skin and/or hair lightening actives
AR085397A1 (en) Combination kinase inhibitors and their uses
ECSP099750A (en) Imidazoquinolines with immunomodulatory properties
EA201101243A1 (en) 3h-imidazo [4,5-c] piridin-6-carboxamide as anti-inflammatory means
WO2008064093A3 (en) Salts and crystal forms of 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile
CU20120084A7 (en) Triazolopyridine derivatives substituted compounds as kinase inhibitors mps-1 and intermediate compounds for their preparation
CR11850A (en) Boronate ester compounds and pharmaceutical compositions thereof
UY31942A (en) Adjuvant formulations comprising combinations of triterpenoids, sterols, immunomodulators, polymers and th2 stimulators, methods of preparation, compositions and applications.
EP3147285A3 (en) Purinone compounds as kinase inhibitors
BR112012017737A2 (en) polyvinylpyrrolidone for stabilizing a solid dispersion of the non-crystalline form of rotigone.
WO2012143416A3 (en) 7 - (3,5 - dimethyl - 4 - isoxazolyl) - 8 - (methyloxy) - 1h - imidazo [4,5 -c] quinoline derivatives
BRPI0519797A (en) Method for the preparation of 2-methyl-1- (2-methylpropyl) -1H-imidazo [4, 5-c] [1, 5] naphthyridin-4-amine, the method for obtaining N4- (2-methylpropyl) -3-nitro [1, 5] naphthyridin-4-amine and method for obtaining 2-methyl-1- (2-methylpropyl) -5-oxido-1H-imidazo [4, 5-c] [1, 5 ] naphthyridine
CO6620050A2 (en) Aminopyrimidine derivatives as modulators of LRRK2

Legal Events

Date Code Title Description
FC Refusal